These factors contribute to the Buy rating as Beam Therapeutics continues to lead innovation in its field. In another report released on January 7, Bernstein also upgraded the stock to a Buy with ...

Fintel reports that on January 29, 2025, Cantor Fitzgerald upgraded their outlook for Beam Therapeutics (NasdaqGS:BEAM) from Neutral to Overweight. As of January 29, 2025, the average one-year ...

Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced ...

Yanan Zhu, an analyst from Wells Fargo, reiterated the Buy rating on Beam Therapeutics (BEAM – Research Report). The associated price target remains the same with $75.00. Discover outperforming ...

Blue Trust Inc. increased its position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 36.3% during the ...